期刊文献+

前列腺癌的近距离放疗与内分泌治疗的比较

Comparison analysis of brachytherapy versus endocrine therapy for patients with prostate cancer
原文传递
导出
摘要 目的比较^125Ⅰ粒子植入近距离放疗与问歇性内分泌治疗在前列腺癌治疗中的效果。方法2001年1月至2006年2月期间,未能接受根治性前列腺切除的前列腺癌患者74例,分为2组,43例采用单纯间歇性内分泌治疗;31例单纯采用近距离^125Ⅰ粒子植入,比较2组患者的临床症状、PSA变化情况、局部进展率、无事件生存率。结果5年生存率和无事件生存率在两组之间比较差异无统计学意义。对于危险分级低危的病例,近距放疗组无事件生存率为77.78%(7/9),内分泌治疗组的无事件生存率为26.67%(4/15),两者之间存在差异(P=0.015);治疗一年后PSA及PSA的变化两组比较,差异均无统计学意义。治疗一年后PSA比较,两组间差异存在统计学意义(P=0.003);治疗前后的PSA的变化差异亦存在统计学意义(P=0.038)。结论对于早期、低危的前列腺癌的治疗首选近距放疗,对于晚期、中高危患者,内分泌治疗与近距放疗效果相近,是否需要联合治疗,需要进一步实践研究。 Objective To study the effects of ^125Ⅰ seed implantation brachytherapy and intermittent hormonal therapy for patients with prostate cancer. Methods From January 2001 to February 2006, a total of 74 patients with prostate cancer, who couldn't undergo radical prostatectomy, were divided into two groups. Forty-three of them received the intermittent endocrine therapy alone, while 31 cases received the close- ~^125Ⅰ seed implantation. Their symptoms, PSA changes, local progression rate and event-free survival in the two groups were comparatively analyzed. Results The total of 74 patients, 5-year survival rate, event-free survival was no significant difference between two groups. However, for the low-risk grade patients, the event-free survival of the brachytherapy group was 77.78% (7/9), the event-free survival rate of endocrine treatment group was 26.67% (4/15). There was a significant differences between the two groups (P=0.015); By the patients of low risk classification, the serum PSA one year after treatment showed significant differences between the two groups(P=0.003); significant difference was also found in PSA (P=0.038) before and after treatment. For the intermediate to high risk grade patients, there was not significant differences between the two groups. Conclusion For patients with early low-risk prostate cancer, brachytherapy is the first choice. For patients with advanced, intermediate-risk and high-risk prostate cancer, the endocrine therapy and brachytherapy show the same effect. Suggestions of the integral therapy needs further study.
出处 《中国男科学杂志》 CAS CSCD 北大核心 2012年第5期44-47,共4页 Chinese Journal of Andrology
关键词 前列腺肿瘤/药物疗法 近距离放射疗法 prostatic neoplasms/drug therapy brachytherapy
  • 相关文献

参考文献9

  • 1Bill-Axelson A, Holmberg L, Ruutu M, et al. Radicalprostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 ;364(18): 1708-1717.
  • 2Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Uro12003;13(2):111-116.
  • 3Roach M 3rc, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65(4): 965-974.
  • 4Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Urol 2003; 13(2):111-116.
  • 5台湾癌症临床研究合作组织.前列腺癌临床诊疗指引.2010:10:22-28.
  • 6Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steriod Biochem Mol Biol 1996; 58(2): 139-146.
  • 7Ellis WJ. Prostate Brachytherapy. Cancer Metastasis Rev 2002; 21(2): 125-129.
  • 8白强,王益鑫.前列腺癌近距离放疗[J].中国男科学杂志,2004,18(4):62-65. 被引量:1
  • 9Maurer U, Wiegel T, Hinkelbein W, et al. Interstitial Brachytherapy with permanent seed implants in early prostate cancer. Front Radiat Ther Oncol 2002; 36 166-170.

二级参考文献12

  • 1Whitmore WF Jr, Hilaris B, Grabstald H. J Urol 1972;108(6): 918-920
  • 2Blasko JC, Grimm PD, Ragde H. Semin Radiat Oncol 1993; 3:240-249
  • 3Arterbery VE. Short-term morbidity from CT-planned I-125 prostate implants. Int J Radiat Oncol Biol Phys 1993, 25:661-667
  • 4Stock RG, Kao J, Stone NN, et al. J Urol 2001; 165:36-439
  • 5Holm HH, Juul N, Pederson JF, et al. J Urol 2002; 167(2 pt 2):985-988
  • 6Barry MJ. Editorial: Quality of life and prostate cancer treatment. J Urol 1999; 162:407
  • 7Langley SE, Laing R. BJU Int 2002; 89:241-249
  • 8Blasko JC, Grimm PD, Sylsvester JE, et al. Radiother Oncol 2000; 57:273-278
  • 9Lee WR, McQuellon RP, Case LD, et al. J Urol 1999;162:403-406
  • 10Arterbery VE, Frazier A, Dalmia P, et al. Semin Surg Oncol 1997; 13:461-464

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部